Description
Larazotide is a synthetic octapeptide zonulin antagonist originally developed by Alba Therapeutics (subsequently Innovate Biopharmaceuticals and 9 Meters Biopharma) as an oral research compound targeting zonulin-mediated intestinal tight junction regulation. The peptide has been extensively investigated in academic and clinical research literature for tight junction pharmacology, zonulin receptor antagonism research, paracellular permeability studies, and comparative research versus other tight junction modulator research compounds. Larazotide reached Phase 3 clinical research (CeDLara program) as an investigational compound but did not meet primary endpoints in reported 2022 results, and it remains an investigational research compound without regulatory approval for any indication. This capsule format delivers 1mg total larazotide per capsule as a dual-salt formulation (500 mcg larazotide sodium + 500 mcg larazotide acetate) — a formulation choice reflecting the differential pH-dependent solubility profiles of the two salt forms across gastrointestinal transit for oral peptide research applications. The oral capsule format uses microcrystalline cellulose (MCC) as the standard capsule excipient in a gelatin capsule shell. The compound is offered here strictly for laboratory research applications investigating oral peptide chemistry, tight junction receptor pharmacology, and comparative research across the tight junction modulator research compound class.
Benefits (Research Focus)
• Tight junction pharmacology research — studied as a research tool for tight junction protein complex (occludin, claudin, ZO-1) pharmacology research
• Zonulin pathway research — investigated for zonulin receptor antagonist activity and downstream tight junction regulation
• Paracellular permeability research — explored for research investigating paracellular versus transcellular transport in epithelial cell research models
• Dual-salt oral formulation chemistry — examined as a dual-salt (sodium + acetate) oral peptide capsule formulation for pH-dependent dissolution research
• Comparative tight junction modulator research — researched alongside other tight junction modulator research compounds in comparative SAR studies
What Researchers Look At
• Zonulin receptor binding activity and downstream tight junction protein complex modulation
• Transepithelial electrical resistance (TEER) endpoints in epithelial cell research models
• Occludin, claudin, and ZO-1 tight junction protein expression and localization research
• Dual-salt (sodium + acetate) formulation dissolution profile characterization across pH gradients
• Comparative pharmacology versus other tight junction modulator research compounds and octapeptide analogs
Quick Specs
• Form: Gelatin capsule
• Total Larazotide per Capsule: 1 mg (dual-salt formulation)
• Larazotide Sodium: 500 mcg per capsule
• Larazotide Acetate: 500 mcg per capsule
• Quantity: 30 capsules per bottle
• Total Larazotide per Bottle: 30 mg
• Other ingredients: Microcrystalline cellulose (MCC, excipient), gelatin capsule shell
• Appearance: Standard gelatin capsule presentation
• Purity: ≥99% (each salt form)
• Identity: MS-verified (per COA)
• Storage: Protect from light
Identity Basics
• Compound: Larazotide (dual-salt formulation: sodium + acetate)
• Synonyms: AT-1001; INN-202; Larazotide sodium; Larazotide acetate; zonulin antagonist octapeptide
• Class: Synthetic octapeptide; zonulin receptor antagonist; tight junction modulator research compound
• Sequence: Gly-Gly-Val-Leu-Val-Gln-Pro-Gly (GGVLVQPG) — 8 amino acids
• Formulation: Dual-salt formulation combining sodium and acetate salt forms at 500 mcg each per capsule
• Originator: Originally developed by Alba Therapeutics; subsequently developed by Innovate Biopharmaceuticals and 9 Meters Biopharma (Phase 3 CeDLara program)
• Molecular Weight: ~726.83 g/mol (larazotide peptide, base form)
• CAS: 258818-34-7 (larazotide acetate); larazotide sodium salt CAS varies by source — verify against supplier COA
⚠️ Disclaimer
- This product is intended for laboratory research use only.
- Not for human or veterinary use.
- Not approved for diagnostic, therapeutic, or medical applications by FDA, Health Canada, or any regulatory authority.
- Investigational research compound only — larazotide did not meet primary endpoints in Phase 3 clinical research (CeDLara program, reported 2022) and remains an investigational compound without regulatory approval for any indication.
- Handle using appropriate laboratory safety procedures and personal protective equipment.
COA Verification Notice: Even if the capsule label or product image states a certain concentration, always go by the COA for the true verified value. We reference the COA to determine the verified concentration and purity of each batch, regardless of what the label or product image indicates.
Janoshik COA — Third-Party Testing
• [COA links for the Larazotide 1mg × 30 capsule batch to be added once Janoshik testing is complete]
